Oxyphenbutazone Anhydrous

Oxyphenbutazone Anhydrous

SCHEMBL25857

CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGS1PTGS2

The experimentally established mechanism targets of Oxyphenbutazone Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 known ✓ P23219 2/20 1.00
LMNA P02545 3/20 1.00
RAB9A P51151 3/20 1.00
ALDH1A1 P00352 2/20 1.00
CYP3A4 P08684 2/20 1.00
MAPK1 P28482 2/20 1.00
CYP1A2 P05177 2/20 1.00
CYP2C9 P11712 2/20 1.00
CYP2C19 P33261 2/20 1.00
TP53 P04637 1/20 1.00
MAPT P10636 1/20 1.00
HPGD P15428 1/20 1.00
NAPRT Q6XQN6 1/20 1.00
ABCB11 O95342 1/20 0.49
KDM4E B2RXH2 2/20 0.43
PKM P14618 1/20 0.43
GRM2 Q14416 6/20 0.42
GAA P10253 2/20 0.40
NPC1 O15118 1/20 0.40
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxyphenbutazone Anhydrous SCHEMBL5316370 1.00 LMNA (1.00) LMNARAB9AALDH1A1CYP3A4PTGS1
Oxyphenbutazone Anhydrous SCHEMBL11337449 1.00 LMNA (1.00) LMNARAB9AALDH1A1CYP3A4PTGS1
Oxyphenbutazone Anhydrous SCHEMBL25856 1.00 LMNA (1.00) LMNARAB9AALDH1A1CYP3A4PTGS1
Oxyphenbutazone Anhydrous SCHEMBL3182776 0.99 LMNA (0.97) LMNARAB9AALDH1A1CYP3A4PTGS1
Oxyphenbutazone Anhydrous SCHEMBL1263248 0.99 LMNA (0.97) LMNARAB9AALDH1A1CYP3A4PTGS1
Oxyphenbutazone Anhydrous SCHEMBL2525061 0.99 LMNA (0.97) LMNARAB9AALDH1A1CYP3A4PTGS1
Oxyphenbutazone Anhydrous SCHEMBL25854 0.99 LMNA (0.97) LMNARAB9AALDH1A1CYP3A4PTGS1
Oxyphenbutazone Anhydrous SCHEMBL1263243 0.97 LMNA (0.94) LMNARAB9AALDH1A1CYP3A4PTGS1
Oxyphenbutazone Anhydrous SCHEMBL28278628 0.97 LMNA (0.94) LMNARAB9AALDH1A1CYP3A4PTGS1
Oxyphenbutazone Anhydrous SCHEMBL9753930 0.96 LMNA (0.92) LMNARAB9AALDH1A1CYP3A4PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 25230 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122050857-A Method for constructing parkinsonism screening model based on expired metabolites, screening method and related equipment 广东智普生命科技有限公司 2026-05-15 CN claimed
US-20260132404-A1 MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS ALNYLAM PHARMACEUTICALS, INC. (US) 2026-05-14 US claimed
CN-122025119-A Neonatal genetic metabolic disease risk assessment method based on multi-modal collaborative learning 浙江大学 2026-05-12 CN claimed
EP-4724049-A1 MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF Catalent Ontario Limited (CA) 2026-04-15 EP claimed
EP-4714928-A1 A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM WITH A HETEROCYCLIC COMPOUND COMPRISING AT LEAST ONE N-N SINGLE BOND Hilti Aktiengesellschaft (LI) 2026-03-25 EP claimed
EP-4701700-A1 DEVICE FOR SUPPLYING BREATHING GAS Löwenstein Medical Technology S.A. (LU) 2026-03-04 EP claimed
US-20260000741-A1 METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE ACERAGEN INC (US) 2026-01-01 US claimed
EP-4288559-B1 METHOD AND SYSTEM FOR DESIGNING PERSONALIZED THERAPEUTICS AND DIET BASED ON FUNCTIONS OF MICROBIOME TATA CONSULTANCY SERVICES LTD (IN) 2025-11-26 EP claimed
WO-2025217200-A1 SYSTEM AND METHODS FOR DETERMINING AND MEASURING CANNABACEA-BASED TREATMENTS CANNFORMATICS, INC. (US) 2025-10-16 WO claimed
WO-2025199660-A1 THIONOCARBAMATE- AND LIGNIN-COLLECTING COMPOSITIONS Oxiquim S.A. (CL) 2025-10-02 WO claimed
US-4478822-A Drug delivery system utilizing thermosetting gels MERCK & CO., INC. (US) 1984-10-23 US claimed
US-4474752-A DIAMINE MODIFIED POLYOXYETHYLENE-POLYOXYPROPYLENE COPOLYMER MERCK & CO., INC. (US) 1984-10-02 US claimed
US-4415585-A Contraceptive method UNIVERSITY OF ILLINOIS FOUNDATION (US) 1983-11-15 US claimed
EP-0010061-B1 PHARMACEUTICAL PREPARATIONS CONTAINING A MOLLUSC EXTRACT Mc Farlane, Stuart John (NZ) 1983-07-13 EP claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed
US-4216212-A Pyrazolidine anti-inflammatory composition and methods of use THE PROCTER & GAMBLE COMPANY (US) 1980-08-05 US claimed
WO-1980000661-A1 PHARMACEUTICAL PREPARATIONS CROFT J (NZ) 1980-04-17 WO claimed
EP-0010061-A1 Pharmaceutical preparations containing a mollusc extract Mc Farlane, Stuart John (NZ) 1980-04-16 EP claimed
US-4169147-A Novel transient pro-drug forms of phenylbutazone and oxyphenbutazone in compositions and methods of use INTERX RESEARCH CORPORATION (US) 1979-09-25 US claimed
US-4151292-A ANTIINFLAMMATORY SIDE EFFECT INHIBITION USING CHROMENE DERIVATIVES, GASTROINTESTINAL DISORDERS FISONS LIMITED (GB) 1979-04-24 US claimed